St. Luke's Cancer Institute

Boise, Idaho 83712

5 studies enrolling now · 9 studies all time

What they study most

Acute Lymphoblastic Leukemia, Advanced Unresectable or Metastatic Solid Malignancy, B-Cell Non-Hodgkins Lymphoma, Colorectal Adenocarcinoma, EGFR Exon 19 Deletion, EGFR L858R, Follicular Lymphoma, KRAS G12C Lung Cancer, Large B-cell Lymphoma, Mantle Cell Lymphoma, Metastatic Pancreas Adenocarcinoma, Multiple Myeloma

Studies at this site

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer — Recruiting now
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma — Recruiting now
Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study — Recruiting now
Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma — Available (expanded access)
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma — Running, not enrolling
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel — Available (expanded access)
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel — Available (expanded access)
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy — Running, not enrolling
A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response — Completed